1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`
`
`Home / Archive / Volume 94, Issue 1
`
`Article metrics
`
`Article menu
`
`
`
`Review
`Ranibizumab (Lucentis) in neovascular age-related macular
`degeneration: evidence from clinical trials
`
`PDF
`
`Referenced in 1 policy sources
`Tweeted by 1
`Referenced in 3 patents
`
`135 readers on Mendeley
`1 readers on CiteULike
`
`250 Total citations
` Recent citations
`18
`
` Field Citation Ratio
`52
`9.57 Relative Citation Ratio
`
`See more details
`
`
`
`Online download statistics by month:
`
`Article lifetime
`
`Last 6 months
`
`This month
`
`Online download statistics by month: May 2009 to December 2020
`
`Abstract
`
`Full
`
`Pdf
`
`May 2009
`
`326
`
`Jun 2009
`
`189
`
`Jul 2009
`
`194
`
`0
`
`0
`
`0
`
`299
`
`214
`
`130
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`1/12
`
`250
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 1
`
`Joining Petitioner: Apotex
`
`
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`
`
`Home / Archive / Volume 94, Issue 1
`
`Article metrics
`
`Article menu
`
`
`
`Review
`Ranibizumab (Lucentis) in neovascular age-related macular
`degeneration: evidence from clinical trials
`
`
`Referenced in 1 policy sources
`Tweeted by 1
`Referenced in 3 patents
`
`135 readers on Mendeley
`1 readers on CiteULike
`
`250 Total citations
` Recent citations
`18
`
` Field Citation Ratio
`52
`9.57 Relative Citation Ratio
`
`See more details
`
`
`
`Online download statistics by month:
`
`Article lifetime
`
`Last 6 months
`
`This month
`
`Online download statistics by month: May 2009 to December 2020
`
`Abstract
`
`Full
`
`
`May 2009
`
`326
`
`Jun 2009
`
`189
`
`Jul 2009
`
`194
`
`0
`
`0
`
`0
`
`299
`
`214
`
`130
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`1/12
`
`250
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 1
`
`Joining Petitioner: Apotex
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Abstract
`
`Full
`
`
`Aug 2009
`
`206
`
`Sep 2009
`
`311
`
`Oct 2009
`
`412
`
`Nov 2009
`
`330
`
`0
`
`0
`
`0
`
`0
`
`Dec 2009
`
`370
`
`11
`
`87
`
`145
`
`111
`
`110
`
`108
`
`Jan 2010
`
`406
`
`133
`
`244
`
`Feb 2010
`
`364
`
`101
`
`151
`
`Mar 2010
`
`306
`
`102
`
`137
`
`Apr 2010
`
`258
`
`51
`
`99
`
`May 2010
`
`363
`
`101
`
`149
`
`Jun 2010
`
`352
`
`Jul 2010
`
`314
`
`Aug 2010
`
`247
`
`95
`
`71
`
`98
`
`124
`
`96
`
`95
`
`Sep 2010
`
`216
`
`108
`
`109
`
`Oct 2010
`
`279
`
`96
`
`108
`
`Nov 2010
`
`330
`
`108
`
`116
`
`Dec 2010
`
`217
`
`Jan 2011
`
`224
`
`91
`
`76
`
`76
`
`92
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`2/12
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 2
`
`Joining Petitioner: Apotex
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Abstract
`
`Full
`
`
`Feb 2011
`
`237
`
`Mar 2011
`
`216
`
`83
`
`81
`
`Apr 2011
`
`178
`
`116
`
`May 2011
`
`183
`
`Jun 2011
`
`134
`
`Jul 2011
`
`133
`
`Aug 2011
`
`170
`
`Sep 2011
`
`153
`
`Oct 2011
`
`146
`
`Nov 2011
`
`199
`
`Dec 2011
`
`154
`
`Jan 2012
`
`183
`
`Feb 2012
`
`196
`
`Mar 2012
`
`178
`
`Apr 2012
`
`172
`
`May 2012
`
`201
`
`Jun 2012
`
`188
`
`Jul 2012
`
`140
`
`58
`
`40
`
`32
`
`60
`
`52
`
`75
`
`69
`
`47
`
`52
`
`34
`
`34
`
`16
`
`27
`
`23
`
`30
`
`84
`
`83
`
`82
`
`80
`
`51
`
`54
`
`46
`
`77
`
`65
`
`63
`
`40
`
`45
`
`45
`
`53
`
`39
`
`56
`
`43
`
`54
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`3/12
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 3
`
`Joining Petitioner: Apotex
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Abstract
`
`Full
`
`
`Aug 2012
`
`152
`
`Sep 2012
`
`170
`
`Oct 2012
`
`168
`
`Nov 2012
`
`161
`
`Dec 2012
`
`171
`
`Jan 2013
`
`176
`
`Feb 2013
`
`873
`
`Mar 2013
`
`153
`
`Apr 2013
`
`189
`
`May 2013
`
`145
`
`Jun 2013
`
`115
`
`Jul 2013
`
`99
`
`Aug 2013
`
`81
`
`Sep 2013
`
`103
`
`Oct 2013
`
`79
`
`Nov 2013
`
`120
`
`Dec 2013
`
`68
`
`Jan 2014
`
`105
`
`32
`
`20
`
`53
`
`30
`
`25
`
`18
`
`34
`
`20
`
`24
`
`18
`
`20
`
`31
`
`20
`
`27
`
`41
`
`25
`
`6
`
`15
`
`58
`
`42
`
`33
`
`43
`
`38
`
`37
`
`41
`
`28
`
`38
`
`27
`
`31
`
`35
`
`25
`
`28
`
`33
`
`41
`
`10
`
`24
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`4/12
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 4
`
`Joining Petitioner: Apotex
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Abstract
`
`Full
`
`
`Feb 2014
`
`118
`
`Mar 2014
`
`80
`
`Apr 2014
`
`120
`
`May 2014
`
`116
`
`Jun 2014
`
`Jul 2014
`
`78
`
`83
`
`Aug 2014
`
`58
`
`Sep 2014
`
`Oct 2014
`
`60
`
`68
`
`Nov 2014
`
`57
`
`Dec 2014
`
`Jan 2015
`
`Feb 2015
`
`Mar 2015
`
`Apr 2015
`
`60
`
`65
`
`67
`
`67
`
`60
`
`May 2015
`
`49
`
`Jun 2015
`
`Jul 2015
`
`35
`
`46
`
`14
`
`16
`
`11
`
`20
`
`15
`
`13
`
`6
`
`17
`
`12
`
`20
`
`11
`
`8
`
`9
`
`7
`
`17
`
`7
`
`9
`
`18
`
`28
`
`19
`
`18
`
`27
`
`20
`
`16
`
`11
`
`20
`
`21
`
`21
`
`17
`
`15
`
`11
`
`11
`
`19
`
`10
`
`30
`
`6
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`5/12
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 5
`
`Joining Petitioner: Apotex
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Abstract
`
`Full
`
`
`Aug 2015
`
`56
`
`Sep 2015
`
`Oct 2015
`
`66
`
`62
`
`Nov 2015
`
`43
`
`Dec 2015
`
`Jan 2016
`
`Feb 2016
`
`Mar 2016
`
`Apr 2016
`
`59
`
`51
`
`58
`
`54
`
`49
`
`May 2016
`
`55
`
`Jun 2016
`
`Jul 2016
`
`50
`
`37
`
`Aug 2016
`
`50
`
`Sep 2016
`
`Oct 2016
`
`53
`
`45
`
`Nov 2016
`
`58
`
`Dec 2016
`
`Jan 2017
`
`37
`
`37
`
`4
`
`10
`
`7
`
`10
`
`9
`
`8
`
`6
`
`7
`
`11
`
`5
`
`5
`
`9
`
`10
`
`13
`
`3
`
`5
`
`7
`
`5
`
`8
`
`9
`
`10
`
`16
`
`7
`
`12
`
`8
`
`11
`
`13
`
`11
`
`8
`
`7
`
`7
`
`13
`
`5
`
`4
`
`61
`
`37
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`6/12
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 6
`
`Joining Petitioner: Apotex
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Abstract
`
`Full
`
`
`Feb 2017
`
`Mar 2017
`
`Apr 2017
`
`42
`
`56
`
`27
`
`May 2017
`
`56
`
`Jun 2017
`
`Jul 2017
`
`75
`
`83
`
`Aug 2017
`
`169
`
`Sep 2017
`
`212
`
`Oct 2017
`
`283
`
`Nov 2017
`
`143
`
`Dec 2017
`
`175
`
`Jan 2018
`
`180
`
`Feb 2018
`
`177
`
`Mar 2018
`
`171
`
`Apr 2018
`
`174
`
`May 2018
`
`174
`
`Jun 2018
`
`150
`
`Jul 2018
`
`173
`
`7
`
`6
`
`15
`
`18
`
`4
`
`5
`
`16
`
`12
`
`10
`
`16
`
`61
`
`55
`
`59
`
`47
`
`63
`
`44
`
`66
`
`88
`
`6
`
`7
`
`8
`
`16
`
`4
`
`5
`
`22
`
`11
`
`10
`
`7
`
`4
`
`11
`
`3
`
`6
`
`16
`
`5
`
`13
`
`5
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`7/12
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 7
`
`Joining Petitioner: Apotex
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Abstract
`
`Full
`
`
`Aug 2018
`
`194
`
`Sep 2018
`
`237
`
`Oct 2018
`
`224
`
`Nov 2018
`
`243
`
`Dec 2018
`
`188
`
`Jan 2019
`
`193
`
`Feb 2019
`
`147
`
`Mar 2019
`
`109
`
`Apr 2019
`
`113
`
`May 2019
`
`134
`
`Jun 2019
`
`183
`
`Jul 2019
`
`128
`
`Aug 2019
`
`163
`
`Sep 2019
`
`131
`
`Oct 2019
`
`120
`
`Nov 2019
`
`139
`
`Dec 2019
`
`231
`
`Jan 2020
`
`128
`
`74
`
`81
`
`53
`
`45
`
`51
`
`48
`
`45
`
`9
`
`10
`
`28
`
`53
`
`41
`
`48
`
`53
`
`46
`
`35
`
`50
`
`44
`
`1
`
`4
`
`11
`
`11
`
`3
`
`8
`
`6
`
`3
`
`9
`
`3
`
`8
`
`6
`
`4
`
`9
`
`2
`
`1
`
`3
`
`8
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`8/12
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 8
`
`Joining Petitioner: Apotex
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Abstract
`
`Full
`
`
`Feb 2020
`
`149
`
`Mar 2020
`
`117
`
`Apr 2020
`
`147
`
`May 2020
`
`149
`
`Jun 2020
`
`182
`
`Jul 2020
`
`128
`
`Aug 2020
`
`76
`
`Sep 2020
`
`139
`
`Oct 2020
`
`128
`
`Nov 2020
`
`88
`
`Dec 2020
`
`146
`
`47
`
`56
`
`59
`
`65
`
`53
`
`46
`
`33
`
`50
`
`44
`
`4
`
`33
`
`6
`
`7
`
`8
`
`3
`
`3
`
`5
`
`2
`
`2
`
`2
`
`5
`
`5
`
`Total
`
`21684
`
`4890
`
`5346
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`9/12
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 9
`
`Joining Petitioner: Apotex
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Consultant Ophthalmologist
`Crewe, Cheshire
`Applications are invited for a Consultant Ophthalmologist at Mid Cheshire Hospitals NHS Foundation Trust
`
`Recruiter: Mid Cheshire Hospitals NHS Foundation Trust
`
`Apply for this job
`
`Clinical Teaching Fellow CT1-3
`Dundee, Dundee City
`NHS Tayside have a vacancy for a Teaching Fellow (CT 1-3 level) in Otolaryngology, Ophthalmology and Plastic Surgery
`
`Recruiter: NHS Tayside
`
`Apply for this job
`
`Consultant Adnexal & Digital Medicine
`London (Central), London (Greater)
` Consultant £82,096- £110,683 per annum, pro rata
`Opportunity for Consultant who has experience in Adnexal Surgery & working with Digital Clinical teams &
`leadership/management experience
`
`Recruiter: Moorfields Eye Hospital NHS Foundation Trust
`
`Apply for this job
`
`Senior Training Fellow in Ophthalmology
`Stafford, Staffordshire
`N/A
`
`R
`
`it
`
`U i
`
`it H
`
`it
`
`l
`
`f N th Midl
`
`d NHS T
`
`t
`
`Other content recommended for you
`
`Notion of tolerating subretinal fluid in neovascular AMD: understanding the fine prints before the
`injection pause
`Ashish Sharma et al., Br J Ophthalmol, 2020
`Updated classification and management of pulmonary hypertension
`Holger M Nef et al., Heart, 2010
`Macular dysfunction in patients with macula-on rhegmatogenous retinal detachments
`Kunihiko Akiyama et al., Br J Ophthalmol, 2019
`Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in
`isolation
`Ashish Sharma et al., Br J Ophthalmol, 2020
`Correction: The development of assessment of SpondyloArthritis international society classification
`criteria for axial spondyloarthritis (part II): validation and final selection
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`10/12
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 10
`
`Joining Petitioner: Apotex
`
`
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`1/19/2021
`BMJ Publishing Group Ltd and European League Against Rheumatism, Ann Rheum Dis, 2019
`
`Cheer Up, Pharma Researchers. You Could Be Working in the Auto Industry
`GenomeWeb, 2007
`Bayer Schering Pharma Renews License for GeneGos MetaCore
`GenomeWeb, 2009
`Assessing the Performance of Pulmonary Function Tests for Detection of ILD in Diffuse Cutaneous
`
`CONTENT
`
`Latest content
`
`Current issue
`
`Archive
`
`Browse by topic
`
`Most read articles
`
`Responses
`
`JOURNAL
`
`About
`
`Editorial board
`
`Sign up for email alerts
`
`Subscribe
`
`Thank you to our reviewers
`
`AUTHORS
`
`Instructions for authors
`
`Submit an article
`
`Editorial policies
`
`Open Access at BMJ
`
`BMJ Author Hub
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`11/12
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 11
`
`Joining Petitioner: Apotex
`
`
`
`1/19/2021
`HELP
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Contact us
`
`Reprints
`
`Permissions
`
`Advertising
`
`Feedback form
`
`
`
`Website Terms & Conditions
`Privacy & Cookies
`Contact BMJ
`
`Cookie settings
`
`Online: ISSN 1468-2079
`
`Print: ISSN 0007-1161
`Copyright © 2020 BMJ Publishing Group Ltd. All rights reserved.
`京ICP备15042040号-3
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`12/12
`
`Mylan Exhibit 1065
`Mylan v. Regeneron, IPR2021-00881
`Page 12
`
`Joining Petitioner: Apotex
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
